

1 **Experimental Gene Therapies for the NCLs**

2
3 Wenfei Liu¹, Sophia-Martha kleine-Holthaus², Saul Herranz-Martin¹, Mikel
4 Aristorena², Sara E. Mole^{3,4}, Alexander J. Smith², Robin R. Ali^{2,5} and
5 Ahad A. Rahim¹

6 7 **Affiliations**

8 1 UCL School of Pharmacy, University College London, UK

9 2 UCL Institute of Ophthalmology, University College London, UK

10 3 MRC Laboratory for Molecular Cell Biology, University College London, Gower
11 Street, London WC1E 6BT, UK

12 4 UCL Great Ormond Street Institute of Child Health, 30 Guildford Street, London
13 WC1N 1EH, UK

14 5 NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation
15 Trust

16
17 * Corresponding author. E-mail address: a.rahim@ucl.ac.uk (A. A. Rahim). Tel: +44
18 (0)2077535889

19 20 21 **Abstract**

22
23 The neuronal ceroid lipofuscinoses (NCLs), also known as Batten disease, are a group
24 of rare monogenic neurodegenerative diseases predominantly affecting children. All
25 NCLs are lethal and incurable and only one has an approved treatment available. To
26 date, 13 NCL subtypes (CLN1-8, CLN10-14) have been identified, based on the
27 particular disease-causing defective gene. The exact functions of NCL proteins and the
28 pathological mechanisms underlying the diseases are still unclear. However, gene
29 therapy has emerged as an attractive therapeutic strategy for this group of conditions.
30 Here we provide a short review discussing updates on the current gene therapy studies
31 for the NCLs.

32 33 34 **Introduction**

35
36 The past 15 years has seen huge advances in viral vector gene delivery technology
37 allowing for more efficient transfer of nucleic acids to cells. This has led to life-saving
38 or life-changing gene therapy clinical trials for immunological (severe combined
39 immunodeficiency due to adenosine deaminase deficiency [1-4] (reviewed by
40 [5]), Wiskott–Aldrich syndrome [6-9], X-linked severe combined immunodeficiency
41 [10-12]), haematological (haemophilia [13-16], myeloid leukaemia [17], Sickle cell
42 disease (reviewed by [18-20]), ophthalmic (reviewed by [21]) (RPE65-associated
43 Leber congenital amaurosis [22-25], Choroideremia [26, 27]) and neurological (spinal
44 muscular atrophy type 1 [28-30], Parkinson’s disease [31, 32] (reviewed by [33])
45 conditions. There are now a growing number of gene therapies being commercialised
46 and licensed for clinical use.

47
48 The application of gene therapy for neurological conditions is technically challenging.
49 The brain is arguably the most complex organ of the body, and identifying and
50 characterising the discrete regions that are affected and how the disease progresses in

1 such an anatomically diverse organ is difficult. Both the skull and the selective blood-
2 brain barrier (BBB) represent physical hurdles that any therapy will need to traverse to
3 gain access to the brain and at sufficient quantities to have a therapeutic effect.
4 Advances in paediatric and adult neurosurgery have meant that the brain can be
5 accessed through the skull and the therapeutic modality can be administered directly
6 into the brain parenchyma or ventricles. Indeed, we discuss in the ‘CLN2 Disease’
7 section how multiple injections may be required. Furthermore, the identification of
8 vectors such as adeno-associated virus serotype 9 (AAV9) that have the ability to cross
9 the blood-brain barrier have opened up the possibility of systemic administrations that
10 could treat both neurological and accompanying visceral pathology. In addition,
11 applying a haematopoietic stem cell (HSC) gene therapy approach offers potential
12 systemic benefits using integrating vectors such as those based on lentiviruses (LVs).
13 An example of this is the preclinical studies of lentiviral based HSC gene therapy using
14 a mouse model of the neurological disorder metachromatic leukodystrophy [34, 35]
15 that led to clinical trials in patients [36, 37]. These advances in gene delivery technology
16 in combination with different routes of administration to the brain have led to gene
17 therapy clinical trials for a wide range of neurological disorders. These include the more
18 common conditions such as Parkinson’s Disease and Alzheimer’s Disease but now also
19 rare paediatric neurodegenerative diseases such as the neuronal ceroid lipofuscinoses
20 (NCLs).

21
22 The NCLs (subtypes and affected proteins summarized in Table 1) have become a
23 popular group of candidate diseases among the rare neurological disorders for pre-
24 clinical and clinical gene therapy studies. There are a number of reasons for this: (i)
25 taken together, the NCLs represent the most frequent neurodegenerative condition in
26 children; (ii) they are monogenic conditions where the defective gene has been
27 identified and characterised; (iii) the development and availability of animal models of
28 disease has furthered our understanding of disease pathology and progression and also
29 provided invaluable tools for pre-clinical testing of new therapies; (iv) there is no major
30 disease modifying treatments available in the clinic for the NCLs (with the recent
31 exception of CLN2 disease) and palliative care remains the main option; (v) some of
32 the NCL proteins (*e.g.* CLN2 and CLN5) are secreted by cells, which allows for cross-
33 correction that could facilitate efficiency of gene therapy. The purpose of this review is
34 to provide an update on the current status of efforts to develop gene therapies for the
35 NCLs. All the preclinical studies and clinical trials are also summarized in Table 2 and
36 3, to allow comparison and future study design.

37 38 39 **CLN1 disease**

40
41 CLN1 disease is caused by homozygous or compound heterozygous mutations in the
42 *PPT1* gene, which leads to a deficiency in the lysosomal enzyme palmitoyl protein
43 thioesterase-1 (PPT1) (Table 1). Disease of onset is typically in infancy but some
44 patients show later onsets varying from late infancy to adulthood [38]. Affected infants
45 usually present with progressive development retardation, seizures and jerks, vision
46 deterioration and motor difficulties, leading to premature death occurring in early and
47 mid-childhood. To model CLN1 disease, *Ppt1* knockout or knock-in mouse models
48 have been developed [39-42] and currently the most commonly used is the *Ppt1*
49 knockout mouse generated by the disruption of exon 9 of the mouse *Ppt1* gene [40].
50 This model recapitulates many pathological and clinical aspects of the human disease

1 including accumulation of lysosomal storage material, gliosis, neuronal and retinal
2 degeneration, motor defects and shortened lifespan of approximately 8 months [40, 43-
3 49].

4
5 Pre-clinical studies using mouse models to investigate gene therapy for CLN1 disease
6 (for an overview see Table 3) were initiated by utilising a recombinant AAV2 vector
7 harbouring human *PPT1* driven by the CAG promoter [47-49]. Brain-targeted delivery
8 of the vector via multi-regional injections resulted in significantly increased PPT1
9 activity in regions of the brain surrounding injection sites, albeit still lower than that
10 measured in wild type mice [47, 49]. Autofluorescent lysosomal inclusions,
11 neurodegeneration and performance in motor coordination tests (the rotarod, pole and
12 ledge tests) were significantly improved but the lifespan of the mice was not increased.
13 Follow up studies using AAV2 pseudotyped with the AAV5 capsid protein led to a
14 better therapeutic efficacy and significantly improved the mouse survival by around 2-
15 5 months [50-52]. Furthermore, brain-targeted AAV2/5 gene therapy in combination
16 with other therapies such as bone marrow transplantation [50], or systemic delivery of
17 PPT1 mimetic (phosphocysteamine) [52] or anti-neuroinflammatory (MW151) [51]
18 have been investigated pre-clinically with the *Ppt1* knockout mice. Gene therapy
19 combined with systemic delivery of PPT1 mimetic [52] or anti-neuroinflammatory
20 drug [51] did not produce dramatic synergistic effects. However, combining with bone
21 marrow transplantation (BMT) largely improved the therapeutic effects of gene
22 therapy, which is particularly noteworthy considering that BMT alone did not show any
23 beneficial effects [50]. The mice treated with AAV+BMT presented with greatly
24 slowed disease progression and prolonged lifespan to around 18 months of age. The
25 authors found that the vector transduction was much higher in the mice treated with
26 AAV+BMT, which might be associated with the gamma radiation accompanying BMT
27 and might directly contribute to the synergy between gene therapy and BMT. More
28 recently, Shyng *et al.* found that dual intracranial and intrathecal administration of
29 AAV9.PPT1 improved the disease pathology in both the forebrain and the spinal cord,
30 leading to a significant delay in the motor function decline and an increase in lifespan
31 to around 19 months, whereas intracranial or intrathecal treatment alone had only a
32 moderate effect [53], indicating that spinal cord pathology is of critical importance and
33 will need to be taken into consideration to optimise a gene therapy strategy for CLN1
34 disease. Collectively, CNS-targeted gene therapy appears promising as a potential
35 strategy for CLN1 disease, but still needs further optimisation with respect to achieving
36 widespread vector transduction and PPT1 correction across the CNS.

37
38 In addition to CNS-targeted gene therapy, ocular gene therapy has also been pre-
39 clinically studied. Intravitreal administration of AAV2.CAG.hPPT1 significantly
40 increased the retinal function and reduced the photoreceptor loss in the *Ppt1* knockout
41 mice [48], suggesting a potential addition to the CNS-directed gene therapy with the
42 aim to improve the quality of life of the patients.

43
44 Recently, the U.S. Food and Drug Administration (FDA) has granted an AAV9 gene
45 therapy clinical trial for CLN1 disease, which is currently at the preparation stage
46 (<https://battendiseasenews.com>).

47 48 49 **CLN2 disease**

1 CLN2 disease is caused by homozygous or compound heterozygous mutations in the
2 *CLN2* gene, which leads to a deficiency in the lysosomal enzyme tripeptidyl-peptidase
3 I (TPP1) (Table 1). The disease has a late-infantile onset around 3 years of age, while
4 some patients may show a later onset [38] or a distinct clinical phenotype [54]. Typical
5 symptoms include development retardation, seizures, motor difficulties and vision loss,
6 leading to premature death that usually occurs around 6-12 years of age [38]. Gene
7 therapy has been extensively studied for CLN2 disease using both small and large
8 animal models (for an overview see Table 3) and subsequent clinical trials have already
9 been initiated (Table 2).

10
11 Gene therapy mediated by various AAV serotypes, such as AAV1 [55], AAV2 [56],
12 AAV5 [56] and AAVrh10 [57, 58], have been investigated using the *Cln2* knockout
13 mice, a model for CLN2 disease devoid of Tpp1 enzyme activity [59]. The mice present
14 with progressive tremor, motor impairments and shortened longevity to around 3-6
15 months of age. Histologically, they show progressive lipofuscin accumulation in
16 various brain regions and neurodegeneration [59]. Brain-targeted (bilateral
17 administration in four brain locations per hemisphere) AAVrh10-mediated gene
18 therapy in 7-week old *Cln2* knockout mice produced wide distribution and high levels
19 of TPP1 in the brain, resulting in significant improvements of the pathology and the
20 phenotype [57]. AAV1 carrying a codon-optimised version of the human *CLN2* gene
21 delivered bilaterally into multiple brain locations also showed dramatic therapeutic
22 efficacy in the *Cln2* deficient mice [55]. Notably, timing of intervention appears to be
23 an important factor in the therapeutic outcomes. Pre-symptomatic administration of
24 gene therapy produced significantly better pathology and phenotype improvements and
25 further extended the lifespan compared with post-symptomatic treatment, highlighting
26 the importance of early intervention before disease onset [55, 58]. These studies
27 highlight the need of multiple intra-parenchymal injections in order to transduce
28 sufficient area of the brain even in small animal models. This does highlight potential
29 difficulties in translation to a brain size of human. An alternative is to investigate
30 systemic delivery of viral vectors with respect to CNS transduction efficiency. Up to
31 date, two studies provide potential systemic AAV delivery strategies with significant
32 CNS TPP1 biodistribution when injected to the adult mice [60, 61] (Table 3). Foley *et al.*
33 tested intra-arterial injection of the AAVrh10.CLN2 vector in combination with
34 mannitol treatment (a blood-brain barrier permeabilizer), which resulted in widespread
35 TPP1 activity in the brain of the wild type mice [60]. In addition, Chen *et al.* tested a
36 novel strategy to increase the CNS biodistribution of intravenously delivered AAV in
37 the CLN2 mice. They identified a specific epitope binding to the brain vascular
38 endothelia of the diseased mice and inserted the epitope into the AAV2 capsid; they
39 showed that intravenous injection of the modified AAV2.TPP1 into adult CLN2 mice
40 resulted in significant TPP1 activity across the CNS and improvement of the
41 neurological pathology and phenotype [61]. The underlying mechanism for this
42 epitope-modified vector is that the viral transduction in the brain endothelia is promoted
43 through the capsid modification and the overexpressed TPP1 is secreted from the
44 endothelia and then taken up by neurons and glia. Together, these two studies provide
45 more options for the gene therapy delivery approaches that can reach the CNS, and
46 hopefully could help to overcome the difficulties arising from multiple intra-cranial
47 injections.

48
49 AAV-mediated gene therapy has also been investigated using a large animal model of
50 CLN2 disease - the *TPP1*-deficient canine Dachshund model [62-64]. Pre-symptomatic

1 intracerebroventricular (ICV) administration of AAV2 vectors harbouring canine
2 *CLN2* resulted in ependymal transduction and TPP1 distribution throughout the CNS,
3 leading to dramatically slowed disease onset and improved survival of the mutant dogs
4 [63]. Notably, the retinal degeneration and visual impairment were not prevented by
5 ICV delivered gene therapy, underlining the necessity of direct ocular treatments [63,
6 64]. Tracy *et al.* attempted to treat the retinal degeneration in the mutant dogs by
7 intravitreal implantation of autologous mesenchymal stem cells that were transduced
8 *ex vivo* with an AAV2.*CLN2* vector prior to the surgery. Treated dog eyes had a reduced
9 number of retinal lesions and the loss of retinal function was slowed, although retinal
10 function was not fully preserved long-term. Of note is that the size of the implanted cell
11 mass decreased over time, which may explain why the therapeutic effect was not
12 maintained [65]. Furthermore, the researchers found clear evidence of peripheral
13 (especially the heart) pathology in the *TPP1*-deficient dogs, which became more
14 obvious as the life span increased after CNS-targeted gene therapy [62]. Blood
15 biomarkers of tissue damage (*i.e.* cardiac troponin, alanine aminotransferase and
16 creatine kinase) increased over time, and the electrocardiography parameters also
17 showed significant changes, none of which was improved by the CNS-targeted gene
18 therapy [62]. Therefore, the systemic manifestations of *CLN2* disease do support a gene
19 therapy strategy that would ideally target multiple body systems.

20
21 On the basis of the above pre-clinical studies, clinical trials of *CLN2* gene therapy have
22 been initiated (Table 2). In 2008, data from the first clinical trial of *CLN2* gene therapy
23 (ClinicalTrials.gov Identifier: NCT00151268; NCT00151216) was reported [66]. Ten
24 *CLN2* patients (3-10 years of age) received injections of AAV2 vectors carrying human
25 *CLN2* driven by the CAG promoter to 12 cortical locations through 3 burr holes per
26 hemisphere. Safety and efficacy were then monitored for 18 months. With respect to
27 safety, severe adverse effects such as seizures were observed post-surgery, but none
28 could be definitely attributed to the vectors; it was unclear whether the adverse effects
29 were due to disease progression, the surgical procedures or the vector administration.
30 Importantly, assessment using the modified Hamburg late infantile neuronal ceroid
31 lipofuscinosis clinical rating scale showed significantly slowed disease progression in
32 the treated patients compared to a combined control group consisting of four untreated
33 patients and historical data. Although the study was small in size and the controls were
34 not matched, randomized or blinded, the data still provided valuable support for more
35 AAV-mediated gene therapy tests for *CLN2* disease and possibly other CNS disorders.
36 Recently, the AAVrh10 vector (ClinicalTrials.gov Identifier: NCT01414985;
37 NCT01161576) has also been proposed to be tested on *CLN2* patients, with the
38 estimated primary completion in late 2020.

41 **CLN3 disease**

42
43 *CLN3* disease is caused by homozygous or compound heterozygous mutations in the
44 *CLN3* gene, which encodes for a transmembrane protein of unknown function (Table
45 1). *In vitro* study shows that *CLN3* is localized to the late endosome-lysosomal
46 compartments of neurons, in both the soma and neurites [67]. Classic juvenile *CLN3*
47 disease patients usually show an onset of disease around 4-8 years of age, mainly with
48 vision loss as the first symptom followed by memory and learning difficulties, seizures,
49 motor and speech dysfunctions [38]. The course of disease is variable between patients,
50 and death usually occurs in the second or third decade [38].

1
2 There are four genetically modified mouse models for CLN3 disease, with two being
3 *Cln3* knockout mouse lines and two *Cln3* knock-in lines [68-71], allowing for
4 evaluation of potential therapeutic approaches using AAV vectors. To date, AAV gene
5 therapy has only been studied with the *Cln3*^{Δex7/8} knock-in mice developed by Cotman
6 *et al* [68] (Table 3). Intracranial injection of AAVrh10 vectors harbouring *CLN3* into
7 newborn *Cln3*^{Δex7/8} knock-in mice resulted in widespread *CLN3* expression in the brain
8 up to 18 months post vector administration [72]. Neuronal lysosomal storage material
9 accumulation and astrogliosis were decreased, but the microglia-mediated
10 inflammatory response remained unchanged [72]. Notably, the authors did not perform
11 motor function tests to evaluate efficacy, as no difference was found between wildtype
12 and untreated mutant mice in the balance beam and grip strength test at 18 months.
13 Bosch *et al.* [73] conducted a study using an approach that utilises AAV9's ability to
14 cross the blood-brain barrier when administered intravenously [74-76]. 1-month old
15 *Cln3*^{Δex7/8} knock-in mice received intravenous injection of scAAV9 vectors carrying the
16 human *CLN3* gene driven by either the ubiquitous CAG promoter or the weaker
17 neuronal MeCP2 promoter [73]. A widespread transgene expression was detected
18 throughout the CNS with lower expression levels in MeCP2-treated brains than CAG-
19 treated brains. Interestingly, the authors found that treatment with the MeCP2 promoter,
20 but not the CAG promoter, resulted in decreased lysosomal accumulations and gliosis
21 and a better performance in the rotarod test in mutant mice up to 5 months after vector
22 administration. Long-term data have not been published so far. Moreover, the early,
23 non-progressive rotarod phenotype described in this study has not been reported
24 consistently in other studies using *Cln3*^{Δex7/8} mice [77, 78].
25

26 Based on preliminary promising data from a clinical trial for CLN6 disease, gene
27 therapy with AAV9 vector containing human *CLN3* (no information on the promoter)
28 has been initiated for a Phase I/II clinical trial (ClinicalTrials.gov Identifier:
29 NCT03770572). The vector will be delivered via a single intrathecal injection and two
30 doses will be tested. The trial is still at the recruiting stage, and the estimated primary
31 completion date is proposed to be in December 2022.
32
33

34 **CLN5 disease**

35

36 CLN5 disease is caused by homozygous or compound heterozygous mutations in the
37 *CLN5* gene (Table 1). There is currently no effective treatment for CLN5 disease.
38 CLN5 patients usually have a disease onset in late infancy, and symptoms include
39 motor dysfunctions, vision loss, seizures and dementia, with variable rates of disease
40 progression leading to death around 14-36 years of age [38, 79]. The function of CLN5
41 is still unclear but it is a soluble lysosomal lumen protein and can be secreted *in vitro*
42 by mammalian cells overexpressing *CLN5* [80-84], which allows a potential
43 mechanism for cross-correction and makes the disease an attractive target for viral
44 vector-mediated gene therapy. Up to date, there have been several mammalian models
45 generated [85-90], among which the most commonly used model in pre-clinical study
46 is the CLN5 Borderdale sheep that presents a mutation at a consensus splice site of the
47 *CLN5* gene resulting in a truncated product [89].
48

49 Pre-clinical studies of AAV- or lentivirus (LV)- mediated gene therapy have been
50 performed in the ovine model of CLN5 disease [91]. *CLN5*-deficient sheep treated with

1 AAV9.ovCLN5 or LV.ovCLN5 vectors (ICV injection combined with
2 intraparenchymal injection into the occipital and parietal cortices) at the pre-
3 symptomatic stage showed improved longevity and were well protected from
4 development of various disease phenotypes by 26-27 months when they were
5 euthanized, except for a much delayed visual impairment [91]. One of the treated sheep
6 was kept alive until 57 months at which point it exhibited blindness and mild
7 behavioural phenotypes. Lack of ocular phenotype correction would suggest that this
8 route of administration provides insufficient transduction of the retina. Therefore,
9 additional ocular gene therapy may be necessary to correct retinal impairments and
10 visual deficits. The authors also investigated AAV-mediated gene therapy in early
11 symptomatic mutant sheep to mimic more closely the clinical scenario of treatment
12 after diagnosis. Whilst the existing pathology and the phenotype were not reversed, the
13 disease progression was slowed with the exception of the visual deficits.

16 CLN6 disease

18 *CLN6* gene encodes a membrane-bound endoplasmic reticulum (ER) protein of
19 unknown function (Table 1). Homozygous or compound heterozygous mutations in this
20 gene cause CLN6 disease, classically an NCL with late infantile onset. Symptoms
21 include developmental retardation, seizures, motor dysfunction and vision loss.
22 Premature death usually occurs between 5 and 12 years of age [92]. Rare cases of fatal,
23 adult onset CLN6 disease without loss of vision, referred to as Kufs disease, have been
24 reported [93].

26 Currently, there is only one mouse model for CLN6 disease, which is the naturally
27 occurring *Cln6^{nclf}* mouse [94-96]. The *Cln6^{nclf}* mouse carries a frameshift mutation in
28 the *Cln6* gene, resulting in a truncated, short-lived protein product. This mouse strain
29 recapitulates CLN6 disease with severe retinal degeneration and widespread
30 neuropathology followed by neuronal loss, behavioural abnormalities and death around
31 1 year of age. Pre-clinical gene therapy approaches have been tested in *Cln6^{nclf}* mice
32 targeting the eye and the brain. Initially, kleine Holthaus *et al.* [97] found that although
33 *Cln6*-deficient mice show a predominant loss of photoreceptor cells, subretinal
34 administration of AAV8, harbouring *CLN6* under the control of the ubiquitous CMV
35 promoter, was not therapeutic. As *CLN6* is expressed in photoreceptors bipolar cells,
36 retinal interneurons located in the inner retina, mutant mice were also treated
37 intravitreally with the AAV2-derived 7m8 vector that was able to transduce bipolar
38 cells, which preserved photoreceptor function and number of photoreceptors. By using
39 bipolar cell-specific promoters (PCP2 or Grm6), the researchers showed that correction
40 of the CLN6 deficiency in bipolar cells was sufficient to slow down the loss of
41 photoreceptors. This study highlighted, for the first time, the importance of bipolar cells
42 in CLN6 disease, but further studies are needed to determine the mechanisms
43 underlying the association between bipolar cells and photoreceptor degeneration in
44 CLN6 disease. It also remains to be seen if bipolar cells play an important role in the
45 retinal degenerations of other forms of NCL.

47 More recently, two groups independently investigated the efficacy of brain-directed
48 gene therapy in *Cln6^{nclf}* mice [98, 99]. Both groups showed that neonatal ICV injections
49 of AAV9 carrying human CLN6 driven by a ubiquitous promoter (CB [98] or CMV
50 [99]) prevented motor deficits, many behavioural abnormalities, neurodegeneration and

1 gliosis in mutant mice. Most notably, in both studies treated mice had a markedly
2 improved lifespan of up to 2 years of age, restoring the natural life span of wild-type
3 mice. Furthermore, Cain *et al.* administered Cynomolgus Macaques intrathecally with
4 the same vector and demonstrated transgene expression throughout the brain without
5 adverse effects in the CNS [98]. Both pre-clinical studies provide encouraging evidence
6 for AAV gene therapy as a therapeutic approach for CLN6 disease. As brain-directed
7 gene therapy is unlikely to prevent the retinal degeneration in CLN6 disease, a
8 combined approach targeting both the brain and the eyes will be important to evaluate
9 the feasibility to combat the loss of vision and neurodegeneration in CLN6 disease. Up
10 to date, a phase I/II clinical trial using intrathecal administration of AAV9.CB.CLN6
11 is currently ongoing for CLN6 disease. Promising preliminary data have been released
12 but have not been published in a peer-reviewed journal (ClinicalTrials.gov Identifier:
13 NCT02725580).

16 **CLN10 disease**

18 CLN10 disease is caused by homozygous or compound heterozygous mutations of
19 the *CTSD* gene encoding for cathepsin D (Table 1). It is a severe congenital NCL, with
20 disease onset before or around birth, though some cases have later onset. Congenital
21 patients present with primary microcephaly, seizures, respiratory failure and rigidity,
22 with death usually occurring within the first weeks after birth [38].

24 Gene therapy has been pre-clinically studied with a *Ctsd* knockout mouse model [100].
25 The *Ctsd* knockout mice develop typical NCL pathology and symptoms like seizures,
26 and usually die around day P26 [101-103]. Profound peripheral pathology in the gut
27 and immune organs has also been reported in these mice. Intestinal mucosa atrophy was
28 first observed around P14 and progressed considerably towards severe intestinal
29 necrosis by the final stage, which was suggested to be an important lethal factor of the
30 mice [96]. Massive destruction of thymus and spleen with severe lymphocyte loss was
31 also shown around the final stage. Such visceral pathologies have not been described
32 in human patients. However, some of the CLN10 cases with later disease onset
33 (infantile or juvenile) did show peripheral pathology such as cardiomyopathy [104,
34 105]. Administration of the AAV1/2 vector harbouring mouse *Ctsd* driven by the
35 CMV/human β -actin promoter to the brain parenchyma of the neonatal *Ctsd* knockout
36 mice led to increased lifespan of around 2 months of age [100]. Not only was the brain
37 pathology rescued, but also the visceral abnormalities were prevented by the brain-
38 directed gene therapy. However, the mice then showed recurrent lethal visceral
39 pathology at around 2 months, without development of brain pathology. The authors
40 also combined brain and peripheral treatment, which further prolonged the lifespan by
41 another 2-4 months [95]. This study suggests vital roles of CTSD in the periphery, and
42 again, calls into question whether other NCL forms would affect peripheral organs
43 especially once lifespan is prolonged.

46 **CLN11 disease**

48 CLN11 disease is an adult onset disease caused by homozygous or compound
49 heterozygous mutations in the *GRN* gene (Table 1). Heterozygous mutations alone
50 cause a frontotemporal lobe dementia [106, 107]. CLN11 gene therapy has only been

1 studied pre-clinically very recently on the *Grn* knockout mice (Table 3). The AAV2/1
2 vectors carrying mouse *Grn* gene driven by the CBA promoter were injected to the
3 medial prefrontal cortex of the *Grn* knockout mice at 10-12 months of age (after disease
4 onset) [108]. Improvement of pathology was observed in various brain regions, despite
5 a very limited transduction area [108]. However, another study that used
6 intracerebroventricular AAV9.CMV.hGRN vectors on the same mouse model reported
7 that *GRN* overexpression caused severe hippocampal neurodegeneration, which was
8 consistently observed over 4 time points (1, 3, 6 and 9 months post-injection) [109]. An
9 ependymal-targeting serotype AAV4 vector carrying the *GRN* gene was also tested but
10 caused T cell infiltration and damage of the ventricular system, suggesting that the brain
11 toxicity was not due to the AAV serotype. The authors also suggested that the
12 hippocampal damage was not simply caused by injection of viral vectors, as no toxicity
13 was observed in the AAV9.*eGFP* or AAV4.*eGFP* treated mice. So, it might be a direct
14 adverse effect of *GRN* overexpression and/or the corresponding adaptive immune
15 response, as the hippocampal neurodegeneration was preceded by marked infiltration
16 of T cells. Such adverse effect was not observed in the study by Arrant et al. [108],
17 discussed above. In that study, although a strong immune response was induced post-
18 injection in the brain parenchyma around the injection site, no adverse functional
19 effects were observed [108]. In addition, the injection route (intra-parenchymal [108]
20 vs. ICV [109]), the vector dosage (7.36e+8 vg [108] vs. 5e+10 vg [109]) and the vector
21 (AAV2/1 [108] vs. AAV9 [109]) are different between these two studies. Therefore,
22 further study is still needed to evaluate the safety of GRN overexpression and gene
23 therapy for CLN11 disease.

24 25 26 **Discussion**

27
28 This review presents an updated concise overview of both pre-clinical and clinical gene
29 therapy studies for NCLs. There has been an international effort to develop gene
30 therapy for NCLs over the past 15 years. Theoretically, the forms of NCLs, such as
31 CLN2, that involve a soluble enzyme that can be secreted from one transduced cell and
32 taken up and cross-correct another cell, is an easier target for gene therapy approaches.
33 However, this has not deterred investigations into the other forms of NCLs involving
34 integral membrane bound proteins, such as CLN6 disease and subsequent clinical trials.
35 This has been led by promising pre-clinical studies in both small and large animal
36 models. It is too early to objectively assess any clinical benefit from these trials in the
37 absence of published data.

38
39 Various gene therapy studies, both within the NCL field but also more generally within
40 neurodegenerative disorders, have highlighted the critical aspect of route of
41 administration of the therapeutic vector and outstanding questions. Given the life-
42 limiting neurodegeneration in the brain, the rationale taken by a number of pre-clinical
43 and clinical studies to administer vector into the cerebrospinal fluid is understandable.
44 This also uses the cerebrospinal fluid as a conduit through which broader
45 biodistribution could be achieved and is important in those conditions where brain
46 pathology is widespread and presents in anatomically distal regions. There are many
47 unanswered questions. Do numerous intraparenchymal administrations have the ability
48 to realistically cover the same brain volume and how many would be required?
49 Furthermore, is there enough distribution of vector from the CSF into the periphery to
50 address the visceral pathology that has been described in this review and numerous

1 other studies? An example of this situation is the CLN2 canine model treated with CNS-
2 targeting gene therapy, which developed visceral pathology once lifespan was extended
3 [57]. The intravenous route of administration using a vector such as AAV9 that crosses
4 the blood-brain barrier or HSC gene therapy could certainly address the peripheral
5 pathology but do these routes provide enough vector or protein, respectively, to the
6 brain compared to direct administration into the CNS? A dual vector administration
7 into the periphery and CNS is a compromise that could provide a robust systemic
8 approach but this needs to be tempered against immune responses to such high doses
9 of vector and the ability to cost-effectively manufacture the required material. A further
10 consideration is, when treating the brain, should we also be treating the eye? Vision
11 impairment and retinal pathology are important features for all NCLs. This could
12 potentially provide both life-saving and quality-of-life preserving benefits for patients.
13

14 To date, various AAV serotypes have been evaluated in pre-clinical NCL gene therapy
15 studies (Table 3). Furthermore, AAV capsid modification to alter the viral tropism is a
16 major area of interest in the gene therapy research field. By capsid shuffling, chemical
17 modification, peptide inserts, *etc*, the tropism of the AAV capsid can be changed or
18 enhanced, which can enhance CNS-targeting gene transfer. An example of this in the
19 gene therapy study for NCLs is the use of an epitope-modified AAV in the CLN2 mouse
20 model, which provides promising therapeutic effects [61]. However, AAV tropism
21 differs between species. A novel AAV capsid with specific tropism needs to be
22 evaluated in higher species such as non-human primates before clinical use.
23

24 In conclusion, significant progress has been made in gene therapy studies for NCLs.
25 The availability and continued improvement in animal models for NCLs provide useful
26 tools for the pre-clinical studies of gene therapy, which has provided promising
27 evidence for clinical trials. New questions are arising and need to be addressed with
28 further research. However, these gene therapy clinical trials offer hope to NCL patients
29 and have the potential to be life-saving or quality of life enhancing treatments.
30

31 **Acknowledgements**

32 SMkH, SHM, SEM, AJR, RRA and AAR were supported by EU Horizon 2020
33 BATCure grant (666918). WL, MA, SEM, AJR and AAR are supported by the UK
34 Medical Research Council (MR/R025134/1). AAR is also funded by UK Medical
35 Research Council Grants (MR/R015325/1, MR/S009434/1, MR/N026101/1 and
36 MR/S036784/1), Action Medical Research (GN2485) and the Wellcome Trust
37 Institutional Strategic Support Fund/UCL Therapeutic Acceleration Support (TAS)
38 Fund (204841/Z/16/Z). SEM benefits from MRC funding to the MRC Laboratory for
39 Molecular Cell Biology University Unit at UCL (award code MC_U12266B) towards
40 lab and office space.

Table 1. NCL subtypes and their affected proteins

Subtype/ Gene	Protein	Location	Function	Clinical phenotype	Pre-clinical AAV gene therapy study
CLN1	Palmitoyl protein thioesterase (PPT1)	Lysosomal matrix	Regulation of synaptic vesicle endo- and exocytosis, endosomal trafficking and lipid metabolism	Infantile, juvenile and adult onset	✓
CLN2	Tripeptidyl peptidase 1 (TPP1)	Lysosomal matrix	Linked to macroautophagy and endocytosis	Late infantile onset	✓
CLN3	CLN3	Golgi and lysosomal membrane	Unknown function	Juvenile onset	✓
CLN4	DnaJ homolog subfamily C member 5 (DNAJC5)	Cytosol, associated with vesicular membrane	Involved in presynaptic endo/exocytosis	Adult (Parry disease)	x
CLN5	CLN5	Lysosomal matrix	Unknown function	Late infantile onset	✓
CLN6	CLN6	Endoplasmic reticulum membrane	Unknown function	Late infantile onset	✓
CLN7	CLN7	Lysosomal membrane	Unknown function	Late infantile and juvenile onset	x
CLN8	CLN8	Endoplasmic reticulum membrane	Unknown function	Late infantile onset	x
CLN10	Cathepsin D (CTSD)	Lysosomal matrix	Involved in apoptosis and autophagy	Congenital	✓
CLN11	Granulin	Extracellular	Unknown function	Adult (Kufs disease)	✓
CLN12	CLN12	Lysosomal membrane	Unknown function	Juvenile onset	x
CLN13	Cathepsin F (CTSF)	Lysosomal matrix	Associated to proteasome degradation and autophagy	Adult (Kufs disease)	x
CLN14	BTB/POZ Domain-Containing Protein KCTD7	Partially associated with plasma membrane	Unknown function	Infantile and late infantile onset	x

Table 2. Clinical trials of NCL gene therapy (www.clinicaltrials.gov)

NCL type	Title	NCT number	Viral vector	Status	No. of participants
CLN2	Genotype - phenotype correlations of late infantile neuronal ceroid lipofuscinosis	NCT 00151268	AAV2.CUhCLN2	Completed	18
CLN2	Safety study of a gene transfer vector for children with late infantile neuronal ceroid lipofuscinosis	NCT00151216	AAV2.CUhCLN2	Phase 1; Active, not recruiting	10
CLN2	Safety study of a gene transfer vector (rh.10) for children with late infantile neuronal ceroid lipofuscinosis	NCT01161576	AAVrh.10.CUhCLN2	Phase 1; Active, not recruiting	25
CLN2	AAVrh.10 administered to children with late infantile neuronal ceroid lipofuscinosis	NCT01414985	AAVrh.10.CUhCLN2	Phase 1/2; Active, not recruiting	8
CLN3	Phase I/IIa gene transfer clinical trial for juvenile neuronal ceroid lipofuscinosis, delivering the CLN3 gene by self-complementary AAV9	NCT03770572	AAV9-CLN3	Phase 1/2; Recruiting	7
CLN6	Phase I/IIa gene transfer clinical trial for variant late infantile neuronal ceroid lipofuscinosis, delivering the CLN6 gene by self-complementary AAV9	NCT02725580	AAV9.CB.CLN6	Phase 1/2; Active, not recruiting	12

Table 3. Pre-clinical gene therapy studies for NCLs

NCL type	Animal model	Viral vector	Promoter	Delivery route	Time of intervention	Reference
CLN1	<i>Ppt1</i> knockout mouse	AAV2	CAG	Intra-brain-parenchymal injection	Neonate	[47, 49]
		AAV2	CAG	Intra-vitreous injection	P18-21 or 8 weeks	[48]
		AAV5	CAG	Intra-brain-parenchymal injection + PPT1 mimetic	Neonate	[52]
		AAV5	CAG	Intra-brain-parenchymal injection + BMT	Neonate	[50]
		AAV5	CAG	Intra-brain-parenchymal injection + MW151	Neonate	[51]
		AAV9	CAG	Intra-brain-parenchymal and/or intrathecal injection	Neonate	[53]
CLN2	<i>Tpp1</i> knockout mouse	AAV2 or AAV5	CMV/CBA	Intra-brain-parenchymal injection	6 weeks	[56]
		AAV1	CMV/CBA	Intra-brain-parenchymal injection	4 or 11 weeks	[55]
		AAVrh.10	CMV/ β -actin	Intra-brain-parenchymal injection	Neonate, 3 weeks or 7 weeks	[57, 58]
	CLN2 deficient Dachshund dog (CLN2: c.325delC)	Epitope-modified AAV2	-	Intravenous injection	6-8 weeks	[61]
		AAV2	CMV/CBA	Intracerebroventricular injection	11-14 weeks	[62-64]
		AAV2	CAG	Intravitreal transplantation of autologous mesenchymal stem cells transduced with the viral vector	14 weeks	[65]
CLN3	<i>Cln3</i> ^{Δex7/8} knock-in mouse	AAVrh.10	CAG	Intra-brain-parenchymal injection	Neonate	[72]
		AAV9	MeCP2 or CMV/CBA	Intravenous injection	1 month	[73]
CLN5						

	<i>CLN5</i> deficient Borderdale sheep (CLN5: c.571+1G>A)	AAV9 or Lentivirus	MNDU3	Intracerebroventricular + intra-brain-parenchymal injection	2-3 months	[91]
		AAV9	CBA	ICV injection	7 months	[91]
CLN6	Naturally occurring <i>Cln6^{ncf}</i> mouse	AAV7m8	CMV, PCP2 or Grm6	Intravitreal injection	P5-6	[97]
		AAV9	CMV	Intracerebroventricular injection	Neonate	[99]
		AAV9	CBA	Intracerebroventricular injection	Neonate	[98]
CLN10	<i>Ctsd</i> knockout mouse	AAV2	CMV/HBA	Intra-brain-parenchymal injection and/or liver/stomach injection	P3	[100]
CLN11	<i>Grn</i> knockout mouse	AAV1	CBA	Intra-brain-parenchymal injection	10-12 months	[108]
		AAV9	CMV	Intracerebroventricular injection	6-8 months	[109]

References

- [1] H.B. Gaspar, S. Cooray, K.C. Gilmour, K.L. Parsley, F. Zhang, S. Adams, E. Bjorkegren, J. Bayford, L. Brown, E.G. Davies, P. Veys, L. Fairbanks, V. Bordon, T. Petropoulou, C. Kinnon, A.J. Thrasher, Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction, *Science translational medicine*, 3 (2011) 97ra80.
- [2] M.P. Cicalese, F. Ferrua, L. Castagnaro, K. Rolfe, E. De Boever, R.R. Reinhardt, J. Appleby, M.G. Roncarolo, A. Aiuti, Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety, *Mol Ther*, 26 (2018) 917-931.
- [3] M.P. Cicalese, F. Ferrua, L. Castagnaro, R. Pajno, F. Barzaghi, S. Giannelli, F. Dionisio, I. Brigida, M. Bonopane, M. Casiraghi, A. Tabucchi, F. Carlucci, E. Grunebaum, M. Adeli, R.G. Bredius, J.M. Puck, P. Stepensky, I. Tezcan, K. Rolfe, E. De Boever, R.R. Reinhardt, J. Appleby, F. Ciceri, M.G. Roncarolo, A. Aiuti, Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency, *Blood*, 128 (2016) 45-54.
- [4] A. Aiuti, F. Cattaneo, S. Galimberti, U. Benninghoff, B. Cassani, L. Callegaro, S. Scaramuzza, G. Andolfi, M. Mirolo, I. Brigida, A. Tabucchi, F. Carlucci, M. Eibl, M. Aker, S. Slavin, H. Al-Mousa, A. Al Ghonaium, A. Ferster, A. Duppenthaler, L. Notarangelo, U. Wintergerst, R.H. Buckley, M. Bregni, S. Markt, M.G. Valsecchi, P. Rossi, F. Ciceri, R. Miniero, C. Bordignon, M.G. Roncarolo, Gene therapy for immunodeficiency due to adenosine deaminase deficiency, *The New England journal of medicine*, 360 (2009) 447-458.
- [5] F. Ferrua, A. Aiuti, Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug, *Hum Gene Ther*, 28 (2017) 972-981.
- [6] S. Hacein-Bey Abina, H.B. Gaspar, J. Blondeau, L. Caccavelli, S. Charrier, K. Buckland, C. Picard, E. Six, N. Himoudi, K. Gilmour, A.M. McNicol, H. Hara, J. Xu-Bayford, C. Rivat, F. Touzot, F. Mavilio, A. Lim, J.M. Treluyer, S. Heritier, F. Lefrere, J. Magalon, I. Pengue-Koyi, G. Honnet, S. Blanche, E.A. Sherman, F. Male, C. Berry, N. Malani, F.D. Bushman, A. Fischer, A.J. Thrasher, A. Galy, M. Cavazzana, Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome, *Jama*, 313 (2015) 1550-1563.
- [7] F. Ferrua, M.P. Cicalese, S. Galimberti, S. Giannelli, F. Dionisio, F. Barzaghi, M. Migliavacca, M.E. Bernardo, V. Calbi, A.A. Assanelli, M. Facchini, C. Fossati, E. Albertazzi, S. Scaramuzza, I. Brigida, S. Scala, L. Basso-Ricci, R. Pajno, M. Casiraghi, D. Canarutto, F.A. Salerio, M.H. Albert, A. Bartoli, H.M. Wolf, R. Fiori, P. Silvani, S. Gattillo, A. Villa, L. Biasco, C. Dott, E.J. Culme-Seymour, K. van Rossem, G. Atkinson, M.G. Valsecchi, M.G. Roncarolo, F. Ciceri, L. Naldini, A. Aiuti, Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study, *Lancet Haematol*, 6 (2019) e239-e253.
- [8] C.J. Braun, K. Boztug, A. Paruzynski, M. Witzel, A. Schwarzer, M. Rothe, U. Modlich, R. Beier, G. Gohring, D. Steinemann, R. Fronza, C.R. Ball, R. Haemmerle, S. Naundorf, K. Kuhlcke, M. Rose, C. Fraser, L. Mathias, R. Ferrari, M.R. Abboud, W. Al-Herz, I. Kondratenko, L. Marodi, H. Glimm, B. Schlegelberger, A. Schambach, M.H. Albert, M. Schmidt, C. von Kalle, C. Klein, Gene therapy for Wiskott-Aldrich

syndrome--long-term efficacy and genotoxicity, *Science translational medicine*, 6 (2014) 227ra233.

[9] A. Aiuti, L. Biasco, S. Scaramuzza, F. Ferrua, M.P. Cicalese, C. Baricordi, F. Dionisio, A. Calabria, S. Giannelli, M.C. Castiello, M. Bosticardo, C. Evangelio, A. Assanelli, M. Casiraghi, S. Di Nunzio, L. Callegaro, C. Benati, P. Rizzardi, D. Pellin, C. Di Serio, M. Schmidt, C. Von Kalle, J. Gardner, N. Mehta, V. Neduva, D.J. Dow, A. Galy, R. Miniero, A. Finocchi, A. Metin, P.P. Banerjee, J.S. Orange, S. Galimberti, M.G. Valsecchi, A. Biffi, E. Montini, A. Villa, F. Ciceri, M.G. Roncarolo, L. Naldini, Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome, *Science*, 341 (2013) 1233151.

[10] E. Mamcarz, S. Zhou, T. Lockey, H. Abdelsamed, S.J. Cross, G. Kang, Z. Ma, J. Condori, J. Dowdy, B. Triplett, C. Li, G. Maron, J.C. Aldave Becerra, J.A. Church, E. Dokmeci, J.T. Love, A.C. da Matta Ain, H. van der Watt, X. Tang, W. Janssen, B.Y. Ryu, S.S. De Ravin, M.J. Weiss, B. Youngblood, J.R. Long-Boyle, S. Gottschalk, M.M. Meagher, H.L. Malech, J.M. Puck, M.J. Cowan, B.P. Sorrentino, Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1, *The New England journal of medicine*, 380 (2019) 1525-1534.

[11] S. Hacein-Bey-Abina, S.Y. Pai, H.B. Gaspar, M. Armant, C.C. Berry, S. Blanche, J. Bleesing, J. Blondeau, H. de Boer, K.F. Buckland, L. Caccavelli, G. Cros, S. De Oliveira, K.S. Fernandez, D. Guo, C.E. Harris, G. Hopkins, L.E. Lehmann, A. Lim, W.B. London, J.C. van der Loo, N. Malani, F. Male, P. Malik, M.A. Marinovic, A.M. McNicol, D. Moshous, B. Neven, M. Oleastro, C. Picard, J. Ritz, C. Rivat, A. Schambach, K.L. Shaw, E.A. Sherman, L.E. Silberstein, E. Six, F. Touzot, A. Tsytsykova, J. Xu-Bayford, C. Baum, F.D. Bushman, A. Fischer, D.B. Kohn, A.H. Filipovich, L.D. Notarangelo, M. Cavazzana, D.A. Williams, A.J. Thrasher, A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency, *The New England journal of medicine*, 371 (2014) 1407-1417.

[12] S.S. De Ravin, X. Wu, S. Moir, S. Anaya-O'Brien, N. Kwatema, P. Littel, N. Theobald, U. Choi, L. Su, M. Marquesen, D. Hilligoss, J. Lee, C.M. Buckner, K.A. Zarembler, G. O'Connor, D. McVicar, D. Kuhns, R.E. Throm, S. Zhou, L.D. Notarangelo, I.C. Hanson, M.J. Cowan, E. Kang, C. Hadigan, M. Meagher, J.T. Gray, B.P. Sorrentino, H.L. Malech, L. Kardava, Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency, *Science translational medicine*, 8 (2016) 335ra357.

[13] S. Rangarajan, L. Walsh, W. Lester, D. Perry, B. Madan, M. Laffan, H. Yu, C. Vettermann, G.F. Pierce, W.Y. Wong, K.J. Pasi, AAV5-Factor VIII Gene Transfer in Severe Hemophilia A, *The New England journal of medicine*, 377 (2017) 2519-2530.

[14] A.C. Nathwani, E.G. Tuddenham, S. Rangarajan, C. Rosales, J. McIntosh, D.C. Linch, P. Chowdary, A. Riddell, A.J. Pie, C. Harrington, J. O'Beirne, K. Smith, J. Pasi, B. Glader, P. Rustagi, C.Y. Ng, M.A. Kay, J. Zhou, Y. Spence, C.L. Morton, J. Allay, J. Coleman, S. Sleep, J.M. Cunningham, D. Srivastava, E. Basner-Tschakarjan, F. Mingozzi, K.A. High, J.T. Gray, U.M. Reiss, A.W. Nienhuis, A.M. Davidoff, Adenovirus-associated virus vector-mediated gene transfer in hemophilia B, *The New England journal of medicine*, 365 (2011) 2357-2365.

[15] A.C. Nathwani, U.M. Reiss, E.G. Tuddenham, C. Rosales, P. Chowdary, J. McIntosh, M. Della Peruta, E. Lheriteau, N. Patel, D. Raj, A. Riddell, J. Pie, S. Rangarajan, D. Bevan, M. Recht, Y.M. Shen, K.G. Halka, E. Basner-Tschakarjan, F.

Mingozzi, K.A. High, J. Allay, M.A. Kay, C.Y. Ng, J. Zhou, M. Cancio, C.L. Morton, J.T. Gray, D. Srivastava, A.W. Nienhuis, A.M. Davidoff, Long-term safety and efficacy of factor IX gene therapy in hemophilia B, *The New England journal of medicine*, 371 (2014) 1994-2004.

[16] L.A. George, S.K. Sullivan, A. Giermasz, J.E.J. Rasko, B.J. Samelson-Jones, J. Ducore, A. Cuker, L.M. Sullivan, S. Majumdar, J. Teitel, C.E. McGuinn, M.V. Ragni, A.Y. Luk, D. Hui, J.F. Wright, Y. Chen, Y. Liu, K. Wachtel, A. Winters, S. Tiefenbacher, V.R. Arruda, J.C.M. van der Loo, O. Zelenaia, D. Takefman, M.E. Carr, L.B. Couto, X.M. Anguela, K.A. High, Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant, *The New England journal of medicine*, 377 (2017) 2215-2227.

[17] I. Tawara, S. Kageyama, Y. Miyahara, H. Fujiwara, T. Nishida, Y. Akatsuka, H. Ikeda, K. Tanimoto, S. Terakura, M. Murata, Y. Inaguma, M. Masuya, N. Inoue, T. Kidokoro, S. Okamoto, D. Tomura, H. Chono, I. Nukaya, J. Mineno, T. Naoe, N. Emi, M. Yasukawa, N. Katayama, H. Shiku, Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS, *Blood*, 130 (2017) 1985-1994.

[18] S. Demirci, N. Uchida, J.F. Tisdale, Gene therapy for sickle cell disease: An update, *Cytotherapy*, 20 (2018) 899-910.

[19] M. Cavazzana, C. Antoniani, A. Miccio, Gene Therapy for beta-Hemoglobinopathies, *Mol Ther*, 25 (2017) 1142-1154.

[20] G. Ferrari, M. Cavazzana, F. Mavilio, Gene Therapy Approaches to Hemoglobinopathies, *Hematol Oncol Clin North Am*, 31 (2017) 835-852.

[21] N. Kumaran, M. Michaelides, A.J. Smith, R.R. Ali, J.W.B. Bainbridge, Retinal gene therapy, *Br Med Bull*, 126 (2018) 13-25.

[22] J.W. Bainbridge, A.J. Smith, S.S. Barker, S. Robbie, R. Henderson, K. Balaggan, A. Viswanathan, G.E. Holder, A. Stockman, N. Tyler, S. Petersen-Jones, S.S. Bhattacharya, A.J. Thrasher, F.W. Fitzke, B.J. Carter, G.S. Rubin, A.T. Moore, R.R. Ali, Effect of gene therapy on visual function in Leber's congenital amaurosis, *The New England journal of medicine*, 358 (2008) 2231-2239.

[23] W.W. Hauswirth, T.S. Aleman, S. Kaushal, A.V. Cideciyan, S.B. Schwartz, L. Wang, T.J. Conlon, S.L. Boye, T.R. Flotte, B.J. Byrne, S.G. Jacobson, Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial, *Hum Gene Ther*, 19 (2008) 979-990.

[24] A.M. Maguire, F. Simonelli, E.A. Pierce, E.N. Pugh, Jr., F. Mingozzi, J. Bencicelli, S. Banfi, K.A. Marshall, F. Testa, E.M. Surace, S. Rossi, A. Lyubarsky, V.R. Arruda, B. Konkle, E. Stone, J. Sun, J. Jacobs, L. Dell'Osso, R. Hertle, J.X. Ma, T.M. Redmond, X. Zhu, B. Hauck, O. Zelenaia, K.S. Shindler, M.G. Maguire, J.F. Wright, N.J. Volpe, J.W. McDonnell, A. Auricchio, K.A. High, J. Bennett, Safety and efficacy of gene transfer for Leber's congenital amaurosis, *The New England journal of medicine*, 358 (2008) 2240-2248.

[25] R.G. Weleber, M.E. Pennesi, D.J. Wilson, S. Kaushal, L.R. Erker, L. Jensen, M.T. McBride, T.R. Flotte, M. Humphries, R. Calcedo, W.W. Hauswirth, J.D. Chulay, J.T. Stout, Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy, *Ophthalmology*, 123 (2016) 1606-1620.

- [26] J.Y. Dong, P.D. Fan, R.A. Frizzell, Quantitative analysis of the packaging capacity of recombinant adeno-associated virus, *Hum Gene Ther*, 7 (1996) 2101-2112.
- [27] R.E. MacLaren, M. Groppe, A.R. Barnard, C.L. Cottrill, T. Tolmachova, L. Seymour, K.R. Clark, M.J. Durning, F.P. Cremers, G.C. Black, A.J. Lotery, S.M. Downes, A.R. Webster, M.C. Seabra, Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial, *Lancet*, 383 (2014) 1129-1137.
- [28] S. Al-Zaidy, A.S. Pickard, K. Kotha, L.N. Alfano, L. Lowes, G. Paul, K. Church, K. Lehman, D.M. Sproule, O. Dabbous, B. Maru, K. Berry, W.D. Arnold, J.T. Kissel, J.R. Mendell, R. Shell, Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy, *Pediatr Pulmonol*, 54 (2019) 179-185.
- [29] S.A. Al-Zaidy, J.R. Mendell, From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1, *Pediatr Neurol*, (2019).
- [30] J.R. Mendell, S. Al-Zaidy, R. Shell, W.D. Arnold, L.R. Rodino-Klapac, T.W. Prior, L. Lowes, L. Alfano, K. Berry, K. Church, J.T. Kissel, S. Nagendran, J. L'Italien, D.M. Sproule, C. Wells, J.A. Cardenas, M.D. Heitzer, A. Kaspar, S. Corcoran, L. Braun, S. Likhite, C. Miranda, K. Meyer, K.D. Foust, A.H.M. Burghes, B.K. Kaspar, Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy, *The New England journal of medicine*, 377 (2017) 1713-1722.
- [31] M. Niethammer, C.C. Tang, A. Vo, N. Nguyen, P. Spetsieris, V. Dhawan, Y. Ma, M. Small, A. Feigin, M.J. Durning, M.G. Kaplitt, D. Eidelberg, Gene therapy reduces Parkinson's disease symptoms by reorganizing functional brain connectivity, *Science translational medicine*, 10 (2018).
- [32] S. Palfi, J.M. Gurruchaga, H. Lepetit, K. Howard, G.S. Ralph, S. Mason, G. Gouello, P. Domenech, P.C. Buttery, P. Hantraye, N.J. Tuckwell, R.A. Barker, K.A. Mitrophanous, Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease, *Hum Gene Ther Clin Dev*, 29 (2018) 148-155.
- [33] F.L. Hitti, A.I. Yang, P. Gonzalez-Alegre, G.H. Baltuch, Human gene therapy approaches for the treatment of Parkinson's disease: An overview of current and completed clinical trials, *Parkinsonism Relat Disord*, 66 (2019) 16-24.
- [34] A. Biffi, A. Capotondo, S. Fasano, U. del Carro, S. Marchesini, H. Azuma, M.C. Malaguti, S. Amadio, R. Brambilla, M. Grompe, C. Bordignon, A. Quattrini, L. Naldini, Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice, *J Clin Invest*, 116 (2006) 3070-3082.
- [35] A. Biffi, M. De Palma, A. Quattrini, U. Del Carro, S. Amadio, I. Visigalli, M. Sessa, S. Fasano, R. Brambilla, S. Marchesini, C. Bordignon, L. Naldini, Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells, *J Clin Invest*, 113 (2004) 1118-1129.
- [36] A. Biffi, E. Montini, L. Lorioli, M. Cesani, F. Fumagalli, T. Plati, C. Baldoli, S. Martino, A. Calabria, S. Canale, F. Benedicenti, G. Vallanti, L. Biasco, S. Leo, N. Kabbara, G. Zanetti, W.B. Rizzo, N.A. Mehta, M.P. Cicalese, M. Casiraghi, J.J. Boelens, U. Del Carro, D.J. Dow, M. Schmidt, A. Assanelli, V. Neduva, C. Di Serio, E. Stupka, J. Gardner, C. von Kalle, C. Bordignon, F. Ciceri, A. Rovelli, M.G. Roncarolo, A. Aiuti, M. Sessa, L. Naldini, Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy, *Science*, 341 (2013) 1233158.

- [37] M. Sessa, L. Lorioli, F. Fumagalli, S. Acquati, D. Redaelli, C. Baldoli, S. Canale, I.D. Lopez, F. Morena, A. Calabria, R. Fiori, P. Silvani, P.M. Rancoita, M. Gabaldo, F. Benedicenti, G. Antonioli, A. Assanelli, M.P. Cicalese, U. Del Carro, M.G. Sora, S. Martino, A. Quattrini, E. Montini, C. Di Serio, F. Ciceri, M.G. Roncarolo, A. Aiuti, L. Naldini, A. Biffi, Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial, *Lancet*, 388 (2016) 476-487.
- [38] D.A. Nita, S.E. Mole, B.A. Minassian, Neuronal ceroid lipofuscinoses, *Epileptic Disord*, 18 (2016) 73-88.
- [39] A. Bouchelion, Z. Zhang, Y. Li, H. Qian, A.B. Mukherjee, Mice homozygous for c.451C>T mutation in *Cln1* gene recapitulate INCL phenotype, *Ann Clin Transl Neurol*, 1 (2014) 1006-1023.
- [40] P. Gupta, A.A. Soyombo, A. Atashband, K.E. Wisniewski, J.M. Shelton, J.A. Richardson, R.E. Hammer, S.L. Hofmann, Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice, *Proceedings of the National Academy of Sciences of the United States of America*, 98 (2001) 13566-13571.
- [41] A. Jalanko, J. Vesa, T. Manninen, C. von Schantz, H. Minye, A.L. Fabritius, T. Salonen, J. Rapola, M. Gentile, O. Kopra, L. Peltonen, Mice with *Ppt1Deltaex4* mutation replicate the INCL phenotype and show an inflammation-associated loss of interneurons, *Neurobiol Dis*, 18 (2005) 226-241.
- [42] J.N. Miller, A.D. Kovacs, D.A. Pearce, The novel *Cln1*(R151X) mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppression therapy, *Hum Mol Genet*, 24 (2015) 185-196.
- [43] E. Bible, P. Gupta, S.L. Hofmann, J.D. Cooper, Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis, *Neurobiol Dis*, 16 (2004) 346-359.
- [44] J.T. Dearborn, S.K. Harmon, S.C. Fowler, K.L. O'Malley, G.T. Taylor, M.S. Sands, D.F. Wozniak, Comprehensive functional characterization of murine infantile Batten disease including Parkinson-like behavior and dopaminergic markers, *Sci Rep*, 5 (2015) 12752.
- [45] C. Kielar, L. Maddox, E. Bible, C.C. Pontikis, S.L. Macauley, M.A. Griffey, M. Wong, M.S. Sands, J.D. Cooper, Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis, *Neurobiol Dis*, 25 (2007) 150-162.
- [46] S.L. Macauley, D.F. Wozniak, C. Kielar, Y. Tan, J.D. Cooper, M.S. Sands, Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouse, *Experimental neurology*, 217 (2009) 124-135.
- [47] M. Griffey, E. Bible, C. Vogler, B. Levy, P. Gupta, J. Cooper, M.S. Sands, Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis, *Neurobiol Dis*, 16 (2004) 360-369.
- [48] M. Griffey, S.L. Macauley, J.M. Ogilvie, M.S. Sands, AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis, *Mol Ther*, 12 (2005) 413-421.
- [49] M.A. Griffey, D. Wozniak, M. Wong, E. Bible, K. Johnson, S.M. Rothman, A.E. Wentz, J.D. Cooper, M.S. Sands, CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis, *Mol Ther*, 13 (2006) 538-547.

- [50] S.L. Macauley, M.S. Roberts, A.M. Wong, F. McSloy, A.S. Reddy, J.D. Cooper, M.S. Sands, Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis, *Annals of neurology*, 71 (2012) 797-804.
- [51] S.L. Macauley, A.M. Wong, C. Shyng, D.P. Augner, J.T. Dearborn, Y. Pearse, M.S. Roberts, S.C. Fowler, J.D. Cooper, D.M. Watterson, M.S. Sands, An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis, *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 34 (2014) 13077-13082.
- [52] M.S. Roberts, S.L. Macauley, A.M. Wong, D. Yilmas, S. Hohm, J.D. Cooper, M.S. Sands, Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis, *J Inherit Metab Dis*, 35 (2012) 847-857.
- [53] C. Shyng, H.R. Nelvagal, J.T. Dearborn, J. Tyynela, R.E. Schmidt, M.S. Sands, J.D. Cooper, Synergistic effects of treating the spinal cord and brain in CLN1 disease, *Proceedings of the National Academy of Sciences of the United States of America*, 114 (2017) E5920-E5929.
- [54] Y. Sun, R. Almomani, G.J. Breedveld, G.W. Santen, E. Aten, D.J. Lefeber, J.I. Hoff, E. Brusse, F.W. Verheijen, R.M. Verdijk, M. Kriek, B. Oostra, M.H. Breuning, M. Losekoot, J.T. den Dunnen, B.P. van de Warrenburg, A.J. Maat-Kievit, Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 disease), *Hum Mutat*, 34 (2013) 706-713.
- [55] M.A. Cabrera-Salazar, E.M. Roskelley, J. Bu, B.L. Hodges, N. Yew, J.C. Dodge, L.S. Shihabuddin, I. Sohar, D.E. Sleat, R.K. Scheule, B.L. Davidson, S.H. Cheng, P. Lobel, M.A. Passini, Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease, *Mol Ther*, 15 (2007) 1782-1788.
- [56] M.A. Passini, J.C. Dodge, J. Bu, W. Yang, Q. Zhao, D. Sondhi, N.R. Hackett, S.M. Kaminsky, Q. Mao, L.S. Shihabuddin, S.H. Cheng, D.E. Sleat, G.R. Stewart, B.L. Davidson, P. Lobel, R.G. Crystal, Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis, *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 26 (2006) 1334-1342.
- [57] D. Sondhi, N.R. Hackett, D.A. Peterson, J. Stratton, M. Baad, K.M. Travis, J.M. Wilson, R.G. Crystal, Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector, *Mol Ther*, 15 (2007) 481-491.
- [58] D. Sondhi, D.A. Peterson, A.M. Edelstein, K. del Fierro, N.R. Hackett, R.G. Crystal, Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis, *Experimental neurology*, 213 (2008) 18-27.
- [59] D.E. Sleat, J.A. Wiseman, M. El-Banna, K.H. Kim, Q. Mao, S. Price, S.L. Macauley, R.L. Sidman, M.M. Shen, Q. Zhao, M.A. Passini, B.L. Davidson, G.R. Stewart, P. Lobel, A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration, *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 24 (2004) 9117-9126.

- [60] C.P. Foley, D.G. Rubin, A. Santillan, D. Sondhi, J.P. Dyke, R.G. Crystal, Y.P. Gobin, D.J. Ballon, Intra-arterial delivery of AAV vectors to the mouse brain after mannitol mediated blood brain barrier disruption, *J Control Release*, 196 (2014) 71-78.
- [61] Y.H. Chen, M. Chang, B.L. Davidson, Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy, *Nat Med*, 15 (2009) 1215-1218.
- [62] M.L. Katz, G.C. Johnson, S.B. Leach, B.G. Williamson, J.R. Coates, R.E.H. Whiting, D.P. Vansteenkiste, M.S. Whitney, Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression, *Gene Ther*, 24 (2017) 215-223.
- [63] M.L. Katz, L. Tecedor, Y. Chen, B.G. Williamson, E. Lysenko, F.A. Wininger, W.M. Young, G.C. Johnson, R.E. Whiting, J.R. Coates, B.L. Davidson, AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease, *Science translational medicine*, 7 (2015) 313ra180.
- [64] R.E. Whiting, C.A. Jensen, J.W. Pearce, L.E. Gillespie, D.E. Bristow, M.L. Katz, Intracerebroventricular gene therapy that delays neurological disease progression is associated with selective preservation of retinal ganglion cells in a canine model of CLN2 disease, *Exp Eye Res*, 146 (2016) 276-282.
- [65] C.J. Tracy, R.E. Whiting, J.W. Pearce, B.G. Williamson, D.P. Vansteenkiste, L.E. Gillespie, L.J. Castaner, J.N. Bryan, J.R. Coates, C.A. Jensen, M.L. Katz, Intravitreal implantation of TPP1-transduced stem cells delays retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis, *Exp Eye Res*, 152 (2016) 77-87.
- [66] S. Worgall, D. Sondhi, N.R. Hackett, B. Kosofsky, M.V. Kekatpure, N. Neyzi, J.P. Dyke, D. Ballon, L. Heier, B.M. Greenwald, P. Christos, M. Mazumdar, M.M. Souweidane, M.G. Kaplitt, R.G. Crystal, Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA, *Hum Gene Ther*, 19 (2008) 463-474.
- [67] S. Oetjen, D. Kuhl, G. Hermey, Revisiting the neuronal localization and trafficking of CLN3 in juvenile neuronal ceroid lipofuscinosis, *Journal of neurochemistry*, 139 (2016) 456-470.
- [68] S.L. Cotman, V. Vrbanac, L.A. Lebel, R.L. Lee, K.A. Johnson, L.R. Donahue, A.M. Teed, K. Antonellis, R.T. Bronson, T.J. Lerner, M.E. MacDonald, *Cln3(Deltaex7/8)* knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth, *Hum Mol Genet*, 11 (2002) 2709-2721.
- [69] S.L. Eliason, C.S. Stein, Q. Mao, L. Tecedor, S.L. Ding, D.M. Gaines, B.L. Davidson, A knock-in reporter model of Batten disease, *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 27 (2007) 9826-9834.
- [70] N.D. Greene, D.L. Bernard, P.E. Taschner, B.D. Lake, N. de Vos, M.H. Breuning, R.M. Gardiner, S.E. Mole, R.L. Nussbaum, H.M. Mitchison, A murine model for juvenile NCL: gene targeting of mouse *Cln3*, *Mol Genet Metab*, 66 (1999) 309-313.
- [71] M.L. Katz, H. Shibuya, P.C. Liu, S. Kaur, C.L. Gao, G.S. Johnson, A mouse gene knockout model for juvenile ceroid-lipofuscinosis (Batten disease), *J Neurosci Res*, 57 (1999) 551-556.

- [72] D. Sondhi, E.C. Scott, A. Chen, N.R. Hackett, A.M. Wong, A. Kubiak, H.R. Nelvagal, Y. Pearse, S.L. Cotman, J.D. Cooper, R.G. Crystal, Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene, *Hum Gene Ther*, 25 (2014) 223-239.
- [73] M.E. Bosch, A. Aldrich, R. Fallet, J. Odvody, M. Burkovetskaya, K. Schubert, J.A. Fitzgerald, K.D. Foust, T. Kielian, Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3), *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 36 (2016) 9669-9682.
- [74] S. Duque, B. Joussemet, C. Riviere, T. Marais, L. Dubreil, A.M. Douar, J. Fyfe, P. Moullier, M.A. Colle, M. Barkats, Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons, *Mol Ther*, 17 (2009) 1187-1196.
- [75] K.D. Foust, A. Poirier, C.A. Pacak, R.J. Mandel, T.R. Flotte, Neonatal intraperitoneal or intravenous injections of recombinant adeno-associated virus type 8 transduce dorsal root ganglia and lower motor neurons, *Hum Gene Ther*, 19 (2008) 61-70.
- [76] A.A. Rahim, A.M. Wong, K. Hoefer, S.M. Buckley, C.N. Mattar, S.H. Cheng, J.K. Chan, J.D. Cooper, S.N. Waddington, Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system, *FASEB J*, 25 (2011) 3505-3518.
- [77] A.D. Kovacs, D.A. Pearce, Finding the most appropriate mouse model of juvenile CLN3 (Batten) disease for therapeutic studies: the importance of genetic background and gender, *Dis Model Mech*, 8 (2015) 351-361.
- [78] J.F. Staropoli, L. Haliw, S. Biswas, L. Garrett, S.M. Holter, L. Becker, S. Skosyrski, P. Da Silva-Buttkus, J. Calzada-Wack, F. Neff, B. Rathkolb, J. Rozman, A. Schrewe, T. Adler, O. Puk, M. Sun, J. Favor, I. Racz, R. Bekeredjian, D.H. Busch, J. Graw, M. Klingenspor, T. Klopstock, E. Wolf, W. Wurst, A. Zimmer, E. Lopez, H. Harati, E. Hill, D.S. Krause, J. Guide, E. Dragileva, E. Gale, V.C. Wheeler, R.M. Boustany, D.E. Brown, S. Breton, K. Ruether, V. Gailus-Durner, H. Fuchs, M.H. de Angelis, S.L. Cotman, Large-scale phenotyping of an accurate genetic mouse model of JNCL identifies novel early pathology outside the central nervous system, *PloS one*, 7 (2012) e38310.
- [79] A. Simonati, R.E. Williams, N. Nardocci, M. Laine, R. Battini, A. Schulz, B. Garavaglia, F. Moro, F. Pezzini, F.M. Santorelli, Phenotype and natural history of variant late infantile ceroid-lipofuscinosis 5, *Dev Med Child Neurol*, 59 (2017) 815-821.
- [80] B. De Silva, J. Adams, S.Y. Lee, Proteolytic processing of the neuronal ceroid lipofuscinosis related lysosomal protein CLN5, *Exp Cell Res*, 338 (2015) 45-53.
- [81] J. Isosomppi, J. Vesa, A. Jalanko, L. Peltonen, Lysosomal localization of the neuronal ceroid lipofuscinosis CLN5 protein, *Hum Mol Genet*, 11 (2002) 885-891.
- [82] F. Jules, E. Sauvageau, K. Dumaresq-Doiron, J. Mazzaferri, M. Haug-Kroper, R. Fluhrer, S. Costantino, S. Lefrancois, CLN5 is cleaved by members of the SPP/SPPL family to produce a mature soluble protein, *Exp Cell Res*, 357 (2017) 40-50.

- [83] A. Moharir, S.H. Peck, T. Budden, S.Y. Lee, The role of N-glycosylation in folding, trafficking, and functionality of lysosomal protein CLN5, *PloS one*, 8 (2013) e74299.
- [84] M.L. Schmiedt, C. Bessa, C. Heine, M.G. Ribeiro, A. Jalanko, A. Kyttila, The neuronal ceroid lipofuscinosis protein CLN5: new insights into cellular maturation, transport, and consequences of mutations, *Hum Mutat*, 31 (2010) 356-365.
- [85] D. Gilliam, A. Kolicheski, G.S. Johnson, T. Mhlanga-Mutangadura, J.F. Taylor, R.D. Schnabel, M.L. Katz, Golden Retriever dogs with neuronal ceroid lipofuscinosis have a two-base-pair deletion and frameshift in CLN5, *Mol Genet Metab*, 115 (2015) 101-109.
- [86] A. Kolicheski, G.S. Johnson, D.P. O'Brien, T. Mhlanga-Mutangadura, D. Gilliam, J. Guo, T.D. Anderson-Sieg, R.D. Schnabel, J.F. Taylor, A. Lebowitz, B. Swanson, D. Hicks, Z.E. Niman, F.A. Wininger, M.C. Carpentier, M.L. Katz, Australian Cattle Dogs with Neuronal Ceroid Lipofuscinosis are Homozygous for a CLN5 Nonsense Mutation Previously Identified in Border Collies, *J Vet Intern Med*, 30 (2016) 1149-1158.
- [87] K. Mizukami, T. Kawamichi, H. Koie, S. Tamura, S. Matsunaga, S. Imamoto, M. Saito, D. Hasegawa, N. Matsuki, S. Tamahara, S. Sato, A. Yabuki, H.S. Chang, O. Yamato, Neuronal ceroid lipofuscinosis in Border Collie dogs in Japan: clinical and molecular epidemiological study (2000-2011), *ScientificWorldJournal*, 2012 (2012) 383174.
- [88] R.D. Jolly, D.G. Arthur, G.W. Kay, D.N. Palmer, Neuronal ceroid-lipofuscinosis in Borderdale sheep, *N Z Vet J*, 50 (2002) 199-202.
- [89] T. Frugier, N.L. Mitchell, I. Tammen, P.J. Houweling, D.G. Arthur, G.W. Kay, O.P. van Diggelen, R.D. Jolly, D.N. Palmer, A new large animal model of CLN5 neuronal ceroid lipofuscinosis in Borderdale sheep is caused by a nucleotide substitution at a consensus splice site (c.571+1G>A) leading to excision of exon 3, *Neurobiol Dis*, 29 (2008) 306-315.
- [90] O. Kopra, J. Vesa, C. von Schantz, T. Manninen, H. Minye, A.L. Fabritius, J. Rapola, O.P. van Diggelen, J. Saarela, A. Jalanko, L. Peltonen, A mouse model for Finnish variant late infantile neuronal ceroid lipofuscinosis, CLN5, reveals neuropathology associated with early aging, *Hum Mol Genet*, 13 (2004) 2893-2906.
- [91] N.L. Mitchell, K.N. Russell, M.P. Wellby, H.E. Wicky, L. Schoderboeck, G.K. Barrell, T.R. Melzer, S.J. Gray, S.M. Hughes, D.N. Palmer, Longitudinal In Vivo Monitoring of the CNS Demonstrates the Efficacy of Gene Therapy in a Sheep Model of CLN5 Batten Disease, *Mol Ther*, 26 (2018) 2366-2378.
- [92] L. Canafoglia, I. Gilioli, F. Invernizzi, V. Sofia, V. Fugnanesi, M. Morbin, L. Chiapparini, T. Granata, S. Binelli, V. Scaioli, B. Garavaglia, N. Nardocci, S.F. Berkovic, S. Franceschetti, Electroclinical spectrum of the neuronal ceroid lipofuscinoses associated with CLN6 mutations, *Neurology*, 85 (2015) 316-324.
- [93] T. Arsov, K.R. Smith, J. Damiano, S. Franceschetti, L. Canafoglia, C.J. Bromhead, E. Andermann, D.F. Vears, P. Cossette, S. Rajagopalan, A. McDougall, V. Sofia, M. Farrell, U. Aguglia, A. Zini, S. Meletti, M. Morbin, S. Mullen, F. Andermann, S.E. Mole, M. Bahlo, S.F. Berkovic, Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6, *American journal of human genetics*, 88 (2011) 566-573.

- [94] R.T. Bronson, L.R. Donahue, K.R. Johnson, A. Tanner, P.W. Lane, J.R. Faust, Neuronal ceroid lipofuscinosis (nclf), a new disorder of the mouse linked to chromosome 9, *Am J Med Genet*, 77 (1998) 289-297.
- [95] H. Gao, R.M. Boustany, J.A. Espinola, S.L. Cotman, L. Srinidhi, K.A. Antonellis, T. Gillis, X. Qin, S. Liu, L.R. Donahue, R.T. Bronson, J.R. Faust, D. Stout, J.L. Haines, T.J. Lerner, M.E. MacDonald, Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse, *American journal of human genetics*, 70 (2002) 324-335.
- [96] R.B. Wheeler, J.D. Sharp, R.A. Schultz, J.M. Joslin, R.E. Williams, S.E. Mole, The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein, *American journal of human genetics*, 70 (2002) 537-542.
- [97] S.M. Kleine Holthaus, J. Ribeiro, L. Abelleira-Hervas, R.A. Pearson, Y. Duran, A. Georgiadis, R.D. Sampson, M. Rizzi, J. Hoke, R. Maswood, S. Azam, U.F.O. Luhmann, A.J. Smith, S.E. Mole, R.R. Ali, Prevention of Photoreceptor Cell Loss in a Cln6(nclf) Mouse Model of Batten Disease Requires CLN6 Gene Transfer to Bipolar Cells, *Mol Ther*, 26 (2018) 1343-1353.
- [98] J.T. Cain, S. Likhite, K.A. White, D.J. Timm, S.S. Davis, T.B. Johnson, C.N. Dennys-Rivers, F. Rinaldi, D. Motti, S. Corcoran, P. Morales, C. Pierson, S.M. Hughes, S.Y. Lee, B.K. Kaspar, K. Meyer, J.M. Weimer, Gene Therapy Corrects Brain and Behavioral Pathologies in CLN6-Batten Disease, *Mol Ther*, (2019).
- [99] S.M.-H. Sophia-Martha kleine Holthaus, Giulia Massaro, Mikel Aristorena, Justin Hoke, Michael P., R.M. Hughes, Olha Semenyuk, Mark Basche, Amna Z. Shah, Izabela P. Klaska, Alexander J. Smith, Sara E., A.A.R. Mole, and Robin R Ali, Neonatal brain-directed gene therapy rescues a mouse model of neurodegenerative CLN6 Batten disease, *bioRxiv*, (2019).
- [100] Z. Shevtsova, M. Garrido, J. Weishaupt, P. Saftig, M. Bahr, F. Luhder, S. Kugler, CNS-expressed cathepsin D prevents lymphopenia in a murine model of congenital neuronal ceroid lipofuscinosis, *The American journal of pathology*, 177 (2010) 271-279.
- [101] P. Saftig, M. Hetman, W. Schmahl, K. Weber, L. Heine, H. Mossmann, A. Koster, B. Hess, M. Evers, K. von Figura, et al., Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells, *EMBO J*, 14 (1995) 3599-3608.
- [102] M. Koike, H. Nakanishi, P. Saftig, J. Ezaki, K. Isahara, Y. Ohsawa, W. Schulz-Schaeffer, T. Watanabe, S. Waguri, S. Kametaka, M. Shibata, K. Yamamoto, E. Kominami, C. Peters, K. von Figura, Y. Uchiyama, Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons, *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 20 (2000) 6898-6906.
- [103] H. Nakanishi, J. Zhang, M. Koike, T. Nishioku, Y. Okamoto, E. Kominami, K. von Figura, C. Peters, K. Yamamoto, P. Saftig, Y. Uchiyama, Involvement of nitric oxide released from microglia-macrophages in pathological changes of cathepsin D-deficient mice, *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 21 (2001) 7526-7533.
- [104] S. Doccini, S. Sartori, S. Maeser, F. Pezzini, S. Rossato, F. Moro, I. Toldo, M. Przybylski, F.M. Santorelli, A. Simonati, Early infantile neuronal ceroid lipofuscinosis (CLN10 disease) associated with a novel mutation in CTSD, *J Neurol*, 263 (2016) 1029-1032.

- [105] J. Hersheson, D. Burke, R. Clayton, G. Anderson, T.S. Jacques, P. Mills, N.W. Wood, P. Gissen, P. Clayton, J. Fearnley, S.E. Mole, H. Houlden, Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology, *Neurology*, 83 (2014) 1873-1875.
- [106] M. Baker, I.R. Mackenzie, S.M. Pickering-Brown, J. Gass, R. Rademakers, C. Lindholm, J. Snowden, J. Adamson, A.D. Sadovnick, S. Rollinson, A. Cannon, E. Dwosh, D. Neary, S. Melquist, A. Richardson, D. Dickson, Z. Berger, J. Eriksen, T. Robinson, C. Zehr, C.A. Dickey, R. Crook, E. McGowan, D. Mann, B. Boeve, H. Feldman, M. Hutton, Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17, *Nature*, 442 (2006) 916-919.
- [107] M. Cruts, I. Gijselinck, J. van der Zee, S. Engelborghs, H. Wils, D. Pirici, R. Rademakers, R. Vandenberghe, B. Dermaut, J.J. Martin, C. van Duijn, K. Peeters, R. Sciot, P. Santens, T. De Pooter, M. Mattheijssens, M. Van den Broeck, I. Cuijt, K. Vennekens, P.P. De Deyn, S. Kumar-Singh, C. Van Broeckhoven, Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21, *Nature*, 442 (2006) 920-924.
- [108] A.E. Arrant, V.C. Onyilo, D.E. Unger, E.D. Roberson, Progranulin Gene Therapy Improves Lysosomal Dysfunction and Microglial Pathology Associated with Frontotemporal Dementia and Neuronal Ceroid Lipofuscinosis, *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 38 (2018) 2341-2358.
- [109] D.A. Amado, J.M. Rieders, F. Diatta, P. Hernandez-Con, A. Singer, J.T. Mak, J. Zhang, E. Lancaster, B.L. Davidson, A.S. Chen-Plotkin, AAV-Mediated Progranulin Delivery to a Mouse Model of Progranulin Deficiency Causes T Cell-Mediated Toxicity, *Mol Ther*, 27 (2019) 465-478.